ストックスクリーナーアプリを入手
71.25
3.47%
2.39
アフターアワーズ：
71.25
前日終値:
$68.86
開ける：
$69.14
24時間の取引高:
3.25M
Relative Volume:
0.59
時価総額：
$27.49B
収益：
$4.82B
当期純損益:
$930.40M
株価収益率:
30.47
EPS:
2.3381
ネットキャッシュフロー:
$1.43B
1週間 パフォーマンス:
+3.79%
1か月 パフォーマンス:
-3.00%
6か月 パフォーマンス:
+7.08%
1年 パフォーマンス:
-14.75%
1日の値動き範囲:
$69.14
$71.57
1週間の範囲:
$67.30
$71.57
52週間の値動き範囲:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
71.25 | 25.99B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
95.40 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
326.54 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.19 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.14 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
94.37 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2026-01-12 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 開始されました | Evercore ISI | In-line |
| 2025-10-21 | 再開されました | Stifel | Buy |
| 2025-09-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 開始されました | Argus | Buy |
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
DexCom: The Growth Thesis Still Needs To Be Proven - Seeking Alpha
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom G7 CGM sensoraccessory that makes stacking multiple days easier - AD HOC NEWS
Enterprise value to revenue forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
DXCMDexcom Inc Latest SEC Filings - Finviz
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Investors to Connect - The National Law Review
Devon Energy Wolfcamp development programshale wells drive long-term output - AD HOC NEWS
Is DexCom Inc (DXCM) a Bargain After 3.8% Drop? GF Value Says Un - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dexcom G7 Professional from Dexcom Inc.Clinic-first CGM for short-term wear - AD HOC NEWS
DXCM ALERT: Securities Fraud Class Action Launched Against DexCom, Inc.December 26, 2025 Deadline - The National Law Review
Did FDA-Backed Stelo Expansion Beyond Insulin Users Just Shift DexCom's (DXCM) Investment Narrative? - Sahm
Enterprise value to EBITDA forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to sales forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to book forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Redefining CGM for people with type 2 diabetes: Dexcom announces Dexcom Flex in Germany - MSN
Price to earnings forward of DexCom, Inc. – SIX:DXCM - TradingView
Devon Energy expands Permian drilling plan, shares tied to oil price swings - AD HOC NEWS
Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)Recover - The National Law Review
DexCom, Inc. (DXCM) Investor Outlook: Seizing a 21.53% Upside in the Booming CGM Market - DirectorsTalk Interviews
Dexcom Inc. extends Stelo reach, shares in focus on NASDAQ - AD HOC NEWS
DexCom Continues Push Towards Universal Glucose Biosensing with Latest AdvancesEarnings Risk Report - dars.gov.et
DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All - Insider Monkey
Did You Lose Money on DexCom, Inc. (DXCM)? Levi & Korsinsky Urges Investors to Act Before December 26, 2025 - The National Law Review
Join Class Action to Recover Losses from DexCom, Inc. (DXCM)Contact Levi & Korsinsky Before December 26, 2025 - The National Law Review
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. InvestorsLead Plaintiff Deadline December 26, 2025 - The National Law Review
Recover Investment Losses: Class Action Initiated Against DexCom, Inc. (DXCM) - The National Law Review
Deutsche Bank Names Top Healthcare Stocks Led by DexCom and Insulet - Investing.com Canada
Dexcom G7 from Dexcom Inc.smaller sensor, quicker warm-up and app-first thinking - Ad-hoc-news.de
The STACK oil gathering system from Devon Energy Corp.quietly critical for getting barrels to mar - Ad-hoc-news.de
DexCom (DXCM) Stock After Three-Year 45% Slide Is The Market Too Pessimistic - Yahoo Finance
Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market - Kavout | AI
Dexcom Inc launches redesigned Stelo app, shares trade around key Nasdaq level - Ad-hoc-news.de
DexCom, Inc. Actuals & Estimates (NASDAQ:DXCM) - TradingView
Devon Energy consensus steady, shares track U.S. oil peers - Ad-hoc-news.de
DexCom, Inc. Actuals & Estimates (HAN:DC4) - TradingView
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now? - The Globe and Mail
Dexcom reports clear analyst support, shares trade below new Deutsche Bank target - Ad-hoc-news.de
Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dexcom Inc (DXCM) Institutional Confidence - TradingKey
DexCom (DXCM) Launches New Stelo App As It Expands Into Four Countries - Sahm
Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DexCom, Inc. Actuals & Estimates (FWB:DC4) - TradingView
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
DexCom Inc. (NASDAQ:DXCM): Why Healthcare Is Watching? - Kalkine Media
DexCom, Inc. Actuals & Estimates (SIX:DXCM.USD) - TradingView
DXCM Forecast — Price Target — Prediction for 2027 - TradingView
Dexcom alerts users after stolen G7 sensors allegedly sold by unauthorized distributor - Class Action Lawsuits
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans - The Globe and Mail
Dexcom - Forbes
Dexcom Inc (DXCM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
Dexcom Inc (DXCM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| FOLETTA MARK G | Director |
Jun 15 '26 |
Sale |
74.13 |
4,000 |
296,540 |
52,852 |
1.99%
大文字化:
|
ボリューム (24 時間):